ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1773

Epidemiology and Outcomes of Raynaud’s Phenomenon Hospitalizations in the US

Rashmi Dhital1, Monica Guma2, Thuthiri Lwin3, Amar Suwal4 and Brian Pedersen1, 1UC San Diego, San Diego, CA, 2UCSD, La Jolla, CA, 3University of California San Diego, San Diego, CA, 4Reading Hospital, Tower Health, Reading, PA

Meeting: ACR Convergence 2022

Keywords: Epidemiology, Raynaud's, Raynaud's phenomenon, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Epidemiology and Public Health Poster III

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: The prevalence of Raynaud’s phenomenon (RP) in the general population is ~3-5%, of which 80–90% are primary. Autoimmune diseases are the most common causes of secondary RP, others may include vibrating tools, drugs, hematologic, vascular, or neurological diseases. A seasonal pattern with worsening RP in winter has been observed. However, the impact on RP hospitalizations in a larger sample has not been studied. The aims of this study were to study the seasonal variations in RP hospitalizations in the U.S and explore the differences in RP hospitalizations based on the presence of autoimmune rheumatic diseases (ARDs).

Methods: We used the National Inpatient Sample (NIS), the largest publicly available inpatient database in the US, to identify adults ≥18 years with a primary hospitalization diagnosis of RP from 2016 to 2019 using the ICD-10 codes I73.00 and I73.01. We used Edwards’ geometric model to analyze the seasonal variation of RP hospitalizations. Pearson’s chi-squared and t-tests were used to compare the characteristics of RP hospitalizations with and without an underlying ARD.

Results: We identified 2,540 hospitalizations with RP (mean age 54±0.8 years; females 77%), highest in winter (30.31%) and lowest in summer (18.50%). The fitted frequency curve showed the peak incidence to be on Jan 19 (peak/low ratio 1.73, 95% CI 1.54-1.95). Trends were similar for RP hospitalizations with or without an underlying ARD (Fig 1).

Of 2,540 hospitalized RP, 1,210 (48%) and 1,330 (52%) were RP with and without gangrene, respectively. Overall, 1,375/2,540 (54%) hospitalized RP had an associated ARD, of which 35% had ≥ 2 ARDs. The association with ARDs was higher in RP with gangrene (815, 67%) than without gangrene (560, 42%). When RP hospitalizations with a single ARD diagnosis were isolated, scleroderma (40%), SLE (14.6%), and RA (6.6%) were most common. Interestingly, while Sjogren’s was noted in ~11% with RP, 95% of those were in association with another ARD (Fig 2).

Hospitalized RP with ARDs had a significantly higher women: men ratio (6x versus 2x, p< 0.001) and Black and Hispanic patients compared to RP without ARDs (25.6 vs 11.7%, and 21.5 vs 8.7%, respectively, p< 0.001). More RPs with ARDs had a concurrent diagnosis of pulmonary hypertension (16.36% vs 3.86%, p< 0.001). On the other hand, hospitalized RP without ARDs consisted of a higher proportion (%) of patients ≥ 45 years old (76.4 vs 65.1, p 0.001) and were associated with tobacco use (47.21 vs 33.45, p 0.002), alcohol use (6.01 vs 0.73, p 0.002), obesity (15.02 vs 9.09, p 0.04), diabetes (16.31 vs 7.27, p 0.002), and migraine (4.29 vs 1.09, p 0.03). The rate of amputation was higher in RP with ARD (17.45% vs 9.44%, p 0.001) (Table 1).

Conclusion:
ARDs most associated with RP hospitalization were scleroderma and SLE. RP with ARDs comprised of higher Black and Hispanic patients, likely related to racial differences in the prevalence of underlying ARDs. RP without ARDs had a higher proportion of tobacco and alcohol use, obesity, and diabetes, suggesting their role in severe RP. As expected, the RP hospitalizations in the U.S. peaked in winter and were lowest in summer; such seasonal variation in hospitalizations might have an implication on dynamically tailoring pharmacotherapy by season.

Supporting image 1

Figure 1. Monthly distribution of Raynaud’s phenomenon (RP)-related hospitalizations in the US

Supporting image 2

Figure 2. Frequency of most common ARD diagnoses in Raynaud’s hospitalizations (35.27% of hospitalizations had ≥1 ARD diagnosis)

Supporting image 3

Table 1. Baseline demographic characteristics, clinical comorbidities, and hospitalization outcomes of Raynaud’s phenomenon (RP)-related hospitalizations (N= 2,540) with or without an underlying autoimmune rheumatic disease (ARD) diagnosis


Disclosures: R. Dhital, None; M. Guma, Pfizer, Novartis, Gilead, Sonoma Bio, Genentech; T. Lwin, None; A. Suwal, None; B. Pedersen, None.

To cite this abstract in AMA style:

Dhital R, Guma M, Lwin T, Suwal A, Pedersen B. Epidemiology and Outcomes of Raynaud’s Phenomenon Hospitalizations in the US [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/epidemiology-and-outcomes-of-raynauds-phenomenon-hospitalizations-in-the-us/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epidemiology-and-outcomes-of-raynauds-phenomenon-hospitalizations-in-the-us/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology